Characterization, quantification and stability of differently prepared amorphous forms of some oral hypoglycaemic agents

References

• Hancock BC. Disordered drug delivery: destiny, dynamics and the Deborah number. J Pharm Pharmacol 2002;54:737–746.
   PubMed Web of Science ®Google Scholar
• Savolainen M, Kogermann K, Heinz A, Aaltonen J, Peltonen L, Strachan C et al. Better understanding of dissolution behaviour of amorphous drugs by in situ solid-state analysis using Raman spectroscopy. Eur J Pharm Biopharm 2009;71:71–79.
   PubMed Web of Science ®Google Scholar
• Stubberud L, Forbes RT. The use of gravimetry for the study of the effect of additives on the moisture induced recrystallization of amorphous lactose. Int J Pharm 1998;163:145–156.
   Google Scholar
• Yoshioka M, Hancock BC, Zografi G. Crystallization of indomethacin from the amorphous state below and above its glass transition temperature. J Pharm Sci 1994;83:1700–1705.
   PubMed Web of Science ®Google Scholar
• Imaizumi H, Nambu N, Nagai T. Stability and several physical properties of amorphous and crystalline form of indomethacin. Chem Pharm Bull 1980;28:2565–2569.
   PubMed Web of Science ®Google Scholar
• Otsuka M, Kaneniwa N. A kinetic study of the crystallization process of noncrystalline indomethacin under isothermal conditions. Chem Pharm Bull 1988;36:4026–4032.
   PubMed Web of Science ®Google Scholar
• Graeser KA, Strachan CJ, Patterson JE, Gordon KC. Physicochemical properties and stability of two differently prepared amorphous forms of simvastatin. Cryst Growth Des 2008;8:128–135.
   Web of Science ®Google Scholar
• Surana R, Pyne A, Suryanarayanan R. Effect of preparation method on physical properties of amorphous trehalose. Pharm Res 2004;21:1167–1176.
   PubMed Web of Science ®Google Scholar
• Jójárt-Laczkovich O, Szabó-Révész P. Amorphization of a crystalline active pharmaceutical ingredient and thermo analytical measurements on this glassy form. J Therm Anal Calorim 2010;102:243–247.
   Web of Science ®Google Scholar
• Otsuka M, Nishizawa J, Fukura N, Sasaki T. Characterization of Poly-amorphous Indomathacin by Tetra-Hertz spectroscopy. J Infrared Milli Tetrahz Waves 2012;33:953–962.
   Web of Science ®Google Scholar
• Kawashima Y, Saito M, Takenaka H. Improvement of solubility and dissolution rate of poorly water-soluble salicylic acid by a spray-drying technique. J Pharm Pharmacol 1975;27:1–5.
   PubMed Web of Science ®Google Scholar
• Florence AT, Salole EG, Stenlake JB. The effect of particle size reduction on digoxin crystal properties. J Pharm Pharmacol 1974;26:479–480.
   PubMed Web of Science ®Google Scholar
• Pikal MJ, Lukes AL, Lang JE. Thermal decomposition of amorphous beta-lactam antibacterials. J Pharm Sci 1977;66:1312–1316.
   PubMed Web of Science ®Google Scholar
• Fagegaltier N, Lamure C, Caron A, Mifsud H, Bauer M. Thermal analysis of amorphous phase in a pharmaceutical drug. J Therm Anal Calorim 1997;48:459–464.
   Google Scholar
• Offerdahl TJ, Salsbury JS, Dong Z, Grant DJ, Schroeder SA, Prakash I et al. Quantitation of crystalline and amorphous forms of anhydrous neotame using 13C CPMAS NMR spectroscopy. J Pharm Sci 2005;94:2591–2605.
   PubMed Web of Science ®Google Scholar
• Chen X, Bates S, Morris KR. Quantifying amorphous content of lactose using parallel beam X-ray powder diffraction and whole pattern fitting. J Pharm Biomed Anal 2001;26:63–72.
   PubMed Web of Science ®Google Scholar
• Pikal MJ, Lukes AL, Lang JE, Gaines K. Quantitative crystallinity determinations for beta-lactam antibiotics by solution calorimetry: correlations with stability. J Pharm Sci 1978;67:767–773.
   PubMed Web of Science ®Google Scholar
• Hancock BC, Parks M. What is the true solubility advantage for amorphous pharmaceuticals? Pharm Res 2000;17:397–404.
   PubMed Web of Science ®Google Scholar
• Shah B, Kakumanu VK, Bansal AK. Analytical techniques for quantification of amorphous/crystalline phases in pharmaceutical solids. J Pharm Sci 2006;95:1641–1665.
   PubMed Web of Science ®Google Scholar
• Chadha R, Kashid N, Jain DVS. Characterization and quantification of amorphous content in some selected parenteral cephalosporins by calorimetric method. J Therm Ana Cal 2005;81:277–284.
   Google Scholar
• Yu L. Amorphous pharmaceutical solids: preparation, characterization and stabilization. Adv Drug Deliv Rev 2001;48:27–42.
   PubMed Web of Science ®Google Scholar
• Kumar Y, Ray PC, Babu JS. Process for the preparation of amorphous form of repaglinide. WO/2005/021524, (2005).
   Google Scholar
• Shavi GP, Kumar AR, Yogendra NU, Armugam K, Ranjan OP, Ginjupalli K et al. Enhanced dissolution and bioavailability of gliclazide using solid dispersion techniques. Int J Drug Deliv 2010;2:49–57.
   Google Scholar
• Purvis T, Mattucci ME, Crisp MT, Johnston KP, Williams RO 3rd. Rapidly dissolving repaglinide powders produced by the ultra-rapid freezing process. AAPS PharmSciTech 2007;8:E58.
   PubMed Web of Science ®Google Scholar
• Taylor LS, Zografi G. Sugar-polymer hydrogen bond interactions in lyophilized amorphous mixtures. J Pharm Sci 1998;87:1615–1621.
   PubMed Web of Science ®Google Scholar